← 홈

전체 프로그램

ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-12 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 4,162개
CGTBiologicstalePersonGen BioTherapeutics (Suzh…Phase 2

anti-MUC1 CAR-T cells (anti-MUC1 CAR-T cells)

Advanced Esophageal Cancer · Malignant Glioma of Brain

#MalignantGliomaofBrain#CGT#Phase2#세포유전치료#CAR-T+3
임상시험 7상태 ACTIVE
CGTAAVBiologicstaleBrain Neurotherapy Bio, Inc.Phase 1

AAV2-GDNF (AAV2-GDNF)

Parkinson's Disease · Parkinson's Disease

#ParkinsonsDisease#CGT#Phase1#세포유전치료#CAR-T+2
임상시험 6상태 RECRUITING
CGTAAVBiologicstaleBrain Neurotherapy Bio, Inc.Phase 1

AAV2-GDNF gene therapy (AAV2-GDNF gene therapy)

Multiple System Atrophy · Multiple System Atrophy

#MultipleSystemAtrophy#CGT#Phase1#세포유전치료#CAR-T+2
임상시험 6상태 RECRUITING
ADCBiologicstaleAstraZenecaPhase 2

AZD0901 (AZD0901)

Gastric Cancer; Gastroesophageal Junction Cancer · Gastric Cancer

#GastricCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 6상태 RECRUITING
ADCBiologicstaleHoffmann-La RochePhase 2

Atirmociclib (Atirmociclib)

Metastatic Breast Cancer · Metastatic Breast Cancer

#MetastaticBreastCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 6상태 RECRUITING
CGTBiologicStephan Grupp MD PhDPhase 2

CART22-65s (Autologous, humanized anti-CD22 CAR T cell therapy, Autologous, humanized anti-CD22 CAR T cell therapy (CART22-65s))

B-cell Acute Lymphoblastic Leukemia; B Lineage Lymphoblastic Lymphoma · CD22

#CD22#CGT#Phase2#세포유전치료#CAR-T+5
임상시험 6상태 RECRUITING
ADCBiologicstaleGSKPhase 2

belantamab mafodotin (Blenrep, GSK2857916, Belantamab mafodotin lyophilized powder)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
효능 ORR 34%임상시험 6상태 ACTIVE
CGTBiologicstaleShanghai AbelZeta Ltd.Phase 1

C-CAR-011 (C-CAR-011)

Refractory Diffuse Large B-Cell Lymphoma · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 6상태 ACTIVE
CGTBiologicstaleShanghai AbelZeta Ltd.Phase 1

C-CAR011 (C-CAR011)

Refractory or Relapsed B-cell Non-Hodgkin Lymphoma · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 6상태 ACTIVE
CGTBiologicstaleShanghai AbelZeta Ltd.Phase 1

C-CAR088 (C-CAR088)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#CGT#Phase1#세포유전치료#CAR-T+2
임상시험 6상태 ACTIVE
CGTBiologicCabaletta BioPhase 2

CABA-201 (CABA-201)

Relapsing Multiple Sclerosis (RMS); Progressive Multiple Sclerosis (PMS) · Pemphigus Vulgaris

#PemphigusVulgaris#CGT#Phase2#세포유전치료#CAR-T+5
임상시험 6상태 RECRUITING
CGTBiologicstaleCity of Hope Medical CenterPhase 1

CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem T-lymphocytes (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem T-lymphocytes)

Central Nervous System Lymphoma · EGFR

#EGFR#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 6상태 RECRUITING
CGTBiologicstaleCity of Hope Medical CenterPhase 1

CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes)

B Acute Lymphoblastic Leukemia; Recurrent Acute Lymphoblastic Leukemia · EGFR

#EGFR#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 6상태 RECRUITING
AntibodystaleMerckPhase 2

pembrolizumab (Keytruda, Coformulated favezelimab/pembrolizumab)

Metastatic Urothelial Carcinoma; Urothelial Neoplasms · Metastatic Urothelial Carcinoma

#MetastaticUrothelialCarcinoma#Antibody#Phase2#항체#면역항체+3
효능 ORR 6.8%임상시험 6상태 RECRUITING
ADCBiologicstaleDaiichi SankyoPhase 1

DS-6000a (DS-6000a)

Renal Cell Carcinoma; Ovarian Tumor · Renal Cell Carcinoma

#RenalCellCarcinoma#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2
임상시험 6상태 RECRUITING
ADCBiologicstaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin Plus Cadonilimab)

Bile Duct Adenocarcinoma Non-Resectable; HER2 Gene Mutation · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
임상시험 6상태 ACTIVE
ADCBiologicstaleRemeGenApproved

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin and Gemcitabine)

Radical Cystectomy; Urothelial Carcinoma · Radical Cystectomy

#RadicalCystectomy#ADC#Approved#항체약물접합체#antibody-drug-conjugate+2
임상시험 6상태 ACTIVE
AntibodystaleAbbVieApproved

adalimumab (Humira, Humira (adalimumab))

Psoriasis · Ulcerative Colitis

#UlcerativeColitis#Antibody#Approved#항체#면역항체+3
효능 ORR 98.4%임상시험 6상태 ACTIVE
ADCBiologicstaleImmunoGen, Inc.Phase 1

IMGN901 (IMGN901)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+1
효능 ORR 0.00%임상시험 6상태 ACTIVE
CGTBiologicstaleNational Institutes of Health C…Phase 2

Individual Patient TCR Transduced PBL (Individual Patient TCR Transduced PBL)

Metastatic HPV-16 Positive Squamous Cell Anal Cancer · Multi-target

#Multi-target#CGT#Phase2#세포유전치료#CAR-T+3
임상시험 6상태 DISCONTINUED

51 / 209 페이지

← 이전다음 →